NCT07867002: Assessing Survival Outcomes With Checkpoint Inhibition ExteNded vs Discontinued in Endometrial Cancer
- State
- Under way
- Phase
- Phase 3
- People
- 140 planned
- Started
- 9 Sep 2026
- Primary completion
- Oct 2032
- Arms
- anti-PD1 maintenance therapy -1 year
- Results
- None posted
- 9 Sep 2026: Trial started
- 9 Oct 2026: Trial registered